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Background: The employment status of workers with chronic hepatitis C has important implications for society
and labor market, for organizations and for the individuals and their economic, social and psychological status. To
evaluate the effects to Peg-IFN-α and RBV treatment on work ability (WAI) and perceived on work stress (PWS). One
hundred forty-four patients consecutive with chronic hepatitis C had been enrolled and treated with
Pegylated-Interferon-α 2b at dose 1.5 mg/kg per week plus daily oral Ribavirin for 12 months. The work
ability (WA) and perceived work stress (PWS) were evaluated. The baseline value of PWS and WAI were
compared to the values obtained at end of months 1, 3, 6, 12 and at follow up. At the end of the study we
have also compared the following groups: pretreatment, end treatment response (ETR), sustained response, no
response, and relapse.
Results: The comparison between end treatment response (ETR) and sustained viral response (SVR) showed a
significant difference in PWS. Comparison between ETR and both non responders (NR) and relapser showed
significant differences in perceived work stress p < 0.01 and work ability index p < 0.05.
Conclusions: HCV workers, treated with Peg-IFNα 2b plus Ribavirin, shows work performance loss, a decrease
of work ability at 1 month and increase in work ability in patients with end on treatment response and in
sustained responders decrease in perceived work stress.
Trial registration: This is not a registered study as an observational study. We measured the job performance
in subjects who was undergoing to the gold standard therapy for Hepatitis C at the moment of our
evaluation.
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Chronic hepatitis C virus (HCV) infection is a world-
wide public health problem with a global prevalence of
2% [1]. According to some estimates, 3-4 million people
are newly infected every year worldwide and 350.000 pa-
tients die every year dye to HCV-related disorders. If left
untreated, chronic HCV infection puts patients at in-
creased risk for cirrhosis, and hepatocellular carcinoma
[2–4]. Rates of sustained virologic response with Peg –
Interferon- Ribavirin therapy remain below 50% and are
after less than 30% among patients who have HCV geno-
type 1 infection and certain baseline characteristics, such
as advanced fibrosis, diabetes, depression and co- infec-
tions [5]. There has been recent interest in the mecha-
nisms by which psychological stress can translate into
immune system activation and release of proinflamma-
tory cytokines [6, 7]. Patients with hepatitis C are stig-
matized in society and stigmatization was associated
with increased anxiety, loss of control and difficult cop-
ing [8]. Fatigue, malaise, concentration difficulties, de-
pression, stress and related negative moods prevail in
the HCV population and may represent barriers to treat-
ment with combination therapy. There is growing inter-
est in the iatrogenic depression that results from
exogenous interferon- alpha (IFN-α) therapy [8–10]. De-
pression, anxiety and fatigue are among the most com-
mon adverse events in IFN/ribavirin treatment and their
cumulative incidence seems to increase during IFN
treatment, but returns to baseline values following com-
pletion of therapy [11]. Research in community based
population documents that depression has an adverse
affect on employment, resulting in job loss, absenteeism
and reduced at work job performance and productivity
[12, 13]. Despite some advances in the treatment of
HCV, interferon is still a component of therapy. To fully
characterize the impact of HCV and the burden of dis-
ease progression, the negative effects of both HCV and
IFN treatment on worker productivity and lifestyle im-
pairment need to be understood [14–17]. Work plays an
important role in the wellbeing for many HCV patients;
in fact the level of satisfaction at work was often as a
strong motivator of social status and for social contacts.
Work stress may have negative impact for both job per-
formance and quality of life.
The aim of the study is to evaluate effects of Peg-
IFN and Ribavirin when being at work and treating
the disease. The purpose is also to evaluate the nega-
tive side effects the treatment brings, measuring per-
ceived work stress (PWS) and work ability (WA)
experienced by patients with Peg-IFN-a plus ribavirin,
according to the response treatment. Such data can
also be used to identify the real costs and benefits of
treating HCV patients and preventing disease
progression.Methods
Study design
This 12 months, observational study was performed in
accordance with the principles of the World Medical As-
sociation Declaration of Helsinki (1997) [18] and was ap-
proved by the local Ethics Committee. It was conducted
in the Department of Internal Medicine of Cannizzaro
Hospital, University of Catania, Catania, Italy. A medical
interview and a physical examination were realized for
all patients included in the study before starting therapy.
All the study was designed as a prospective longitudinal
single-center study. All enrolled patients were included
in the intention-to-treat efficacy analysis and patients
who received at least one dose of Peg-IFN-α 2b (1.5 mg/
kg per week) plus daily oral RBV were included in the
safety analysis. All patients gave informed consent to
study participation before enrollment. Each participant
provides written informed consent before undergoing
any study-related procedure. Patients were informed
about their serological data before the completion of
tests on work performances; they were not informed
about their virological condition.
Patients
Among outpatients of our department 387 patients (age
25–65 years) who had never received a diagnosis of
HCV patients, a total of 144 patients with chronic hepa-
titis C (62 women and 82 men) were consecutively en-
rolled in the study between January 2010 and December
2014 (Table 1). The patients underwent treatment with
Peg-IFN-a 2b + RBV for 12 months. Eligibility criteria
were a history of no previous treatment for HCV infec-
tion age of 25 years or older, weight of 50 to 100 Kg,
chronic infection with HCV genotype 1 and plasma
HCV RNA level of 10.000 IU/ml or greater. Exclusion
criteria were liver disease of other cause positivity tests
for serum hepatitis B surface antigen, positive test for
serum HIV antibodies, negativity for HCV antibodies, al-
coholic liver disease (daily alcohol consumptions > 20 g/
day), and diabetes. The presence of other causes of hepa-
topathy, decompensated cirrhosis, pregnancy, and
known contraindications for Peg-IFN-a or RBV therapy
such as hemoglobinopathies, cardiopathy, hemocroma-
tosis, diabetes mellitus, autoimmune diseases, major
depression or other severe psychiatric pathological con-
ditions, every active illicit treatment, and any drug that
might influence serum lipid levels within the last 12
months were considered causes for ruling out. Patients
undergoing treatment were prospectively asked to
complete questionnaires before, during, and after treat-
ment and follow up. Patients were excluded from the
questionnaire protocol if they were not able to read or
speak Italian. All patients were treated with Peg-IFN-α
2b at dose 1.5 mg/kg per week, plus ribavirin (RBV)
Table 1 Demographic, clinical, histological and virological
characteristics of patients at baseline
Parameter Patients treated with
Peg-IFNα + RBV
N 144
Mean age (years) 43.8 ± 7.8
Sex (M/F) 82/62
Systolic blood pressure (SBP) mmHg 132.6 ± 10.8
Diastolic Blood Pressure (DBP) mmHG 81.8 ± 6.7
Heart Rate (HR) beats/min 81.4 ± 6.6
HCV exposure time (years) 5.64 ± 6.8
BMI (kg/m2) 25.8 ± 4.8
Route of transmission of HCV (No of patients)
Blood transfusion 86






Blue collars (manual labourers) 50
White collars (non manual/office labourers) 94
Laboratory parameters
Plasma glucose (mmol/l) (normal 3.9-6.4) 5.41 ± 0.96
AST (IU/l) (normal 15-50) 162 ± 38
ALT (IU/l) (normal 15-50) 171 ± 44
Viremia (106 IU/ml) 5.04 ± 3.12
CRP (mg/dl) (normal <1.0) 4.6 ± 0.7
HAI (histological activity index) 10.1 ± 3.6
Fig. 1 Flowchart of the present study
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treatment, 1 month, 6 and 12 months after the initiation
of the therapy. A follow-up evaluation was performed 6
months after the end of the planned treatment (Fig. 1
Flowchart).
Laboratory exams
A complete routine chemistry including red cell count,
hemoglobin, white cell count, platelets prothrombin
time, fasting plasma glucose, insulin, C-reactive protein,
blood urea nitrogen, serum creatinine, bilirubin, ALT, as-
partate aminotransferase, alkaline phosphatase, γ-
glutamil transpeptidase, and creatin phosphokinase
levels was performed at every medical visit.
Virological findings
Anti-HCV antibodies were evaluated by using second gen-
eration enzyme-linked immunosorbent assay (Ortho-Diag-
nostic Systems, Raritan, NJ), and positive samples were
confirmed by immunoblotting (RIBA; Chiron Corporation,Emeryville, CA). For hepatitis B virus serological markers,
we used kits (Abbott Laboratories, Chicago, IL). The pres-
ence of antibodies (antinuclear, antimitochondrial, anti-
smooth muscle, and anti-liver-kidney-microsome) was
evaluated by indirect immunofluorescence. Serum HCV
RNA levels have been measured by standardized quantita-
tive polymerase chain reaction (PCR) assay with a lower
limit of detection of < 1,000 IU/mL, using the Amplicor
quantitative PCR system (Roche Diagnostic System Inc.,
Branchburg, NJ). Serum samples negative for HCV RNA
were re-tested using a more sensitive standardized qualita-
tive PCR assay with a lower limit of detection of about 100
IU/mL to confirm HCV-RNA disappearance. HCV geno-
types and subtypes were identified through a modification
of the specific line probe assay (Inno-LiPA system; Innoge-
netics NV, Zwijnaarde, Belgium) as described by Stuyver
et al. [19]. Briefly, primers complementary to the conserved
sequences of the 5 untranslated regions of the different
HCV genotypes were used in the reverse transcription-
PCR. HCV RNA were extracted from patients’ sera and
amplified by reverse transcription-PCR with the incorpor-
ation of biotinylated deoxyuridine triphosphate. Oligo-
nucleotide probes (16-mers) that were specific for the
different HCV genotypes and subtypes were hybridized
with the patient’s amplified viral complementary DNA.
Hybridization was detected with alkaline phosphatase la-
beled streptavidin and nitroblue tetrazolium/5-bromo-4-
chloro-3-indolyl phosphate chromagens. The HCV geno-
types were designated according to the nomenclature pro-
posed by Simmonds et al. [20].Histology
Liver biopsy was realized 6 months before the initiation of
therapy and 6 months after the end of treatment. It was ob-
tained using a modified Menghini technique. The specimen
was fixed in neutral formaldehyde 4% solution for routine
histological processing and evaluation. The Knodell and
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assess the histological grading of the disease [21].
Work ability
The work ability is a tool to record the work ability of em-
ployees. It aims at identifying, at an early stage, health
risks of early retirement an counteracting them [22]. The
questionnaire is aimed at: 1) the estimated current and fu-
ture work ability; 2) diagnosed illness and the number of
absenteeism days in the previous year; 3) the estimated
sickness-related deterioration in the work performance; 4)
mental ability reserves. However, the questions can also
be answered with the help of others, for example works
physicians during the work medical examination. The WA
can be used for individual employees and groups of
workers. The WA has been used and tested on many oc-
casions; this tool is easy to use. The time involved for the
questionnaire is between 10 and 15 minutes. The WAI
evaluates current work ability compared with lifetime and
in relation to the demands of the job, number of current
diseases diagnosed by a physician, estimated work impair-
ment due to diseases. Completion of the questionnaire re-
sults is a score which lies between 7 and 49. A high value
indicates good work ability; a lower value in unsatisfactory
or jeopardized work ability. Depending on the level of
score it is recommended to maintain (score 44-49), sup-
port (score 37-43), improve (score 28-36) or reinstate
(score 7-27) the work ability.
Perceived work stress
Perceived Work Stress is an important part of the overall
job demands. If work stress is becoming too high, this
may result in negative consequences for job performance,
absenteeism, work ability. The perceived work stress ques-
tionnaire comprises six stress factors (boredom, lack of
support, quantitative and qualitative overload, unsatisfac-
tory prospects or salary and unsatisfactory physical work-
ing conditions) and scores on a five point scale (1 = no
stress; 5 = high stress) [23].
Efficacy and safety assessment
All enrolled patients were included in the intention-to-
treat efficacy analysis, and patients who received at least
one dose of IFN-a plus RBV were included in the safety
analysis Data were analyzed by an “intention to treat”
principle. The response to treatment was defined either
on the basis of serum ALT levels or serological presence
of HCV-RNA. Lasting of results was considered as ETR
(end of treatment response) or SVR (sustained response
viral over 6 months after the end of treatment). ETR was
defined as normalization of serum ALT levels during ther-
apy and at the end of therapy associated with absence of
serum HCV-RNA at the end of therapy. A sustained re-
sponse was considered when HCV-RNA absence andALT normalization had been registered at the end of ther-
apy and during the 6-month follow up period. We consid-
ered as relapsers the patients who showed ETR followed
by relapse throughout the follow up period. Patients with
HCV-RNA detectable in the serum at the end of the treat-
ment have been defined as non responders (NR).
Adverse events were assessed by interviews, labora-
tory, and clinical examinations during treatment. They
were graded as mild, moderate, and severe on the basis
of World Health Organization score [18]. The treatment
was definitively stopped in the case of severe events,
such as hematological toxicity, hepatic failure, and no
compliance. In moderate and mild cases of adverse ef-
fects, a dose reduction of 50% was performed, until the
resolution of the event when a full dose was restarted.
Statistical analysis
Data are presented as mean values and standard devia-
tions. The baseline values of each Perceived Work Stress
score and of Work Ability dimension were compared to
these obtained at the end of months 1, 3, 6, 12 as well as
at the end of the follow-up period. Was considered sig-
nificant where lesser than 0.05.
Demographic and laboratory data were compared
using one-way ANOVA. Statistical Analysis System
(SAS/STAT version 6.12; SAS Institute, Cary, NC USA).
Results
Baseline characteristics
Baseline demographic, clinical, histological and viro-
logical characteristics of patients at baseline are reported
in Table 1. The most frequent viral genotype in patients
was 1b (86%) and the main route of transmission of
HCV was blood transfusion (73%). The blue collars
(manual labourers) included in the study were 50 (34%)
while white collars (non manual/office labourers) were
94 (65%) (Table 1).
Course of biohumoral effects before the treatment
The difference of biohumoral tests at t = 0 and 6, 12
months and follow-up were investigated with analysis of
variance and t-test for Equality of Means (n = 144).
AST, ALT and Viremia are decreased (p < 0.01) at 6
months, at 12 months, and at follow-up (Table 2).
The comparison before and after the treatment with
ANOVA test shows a significant decrease (p < 0.01).
Course of perceived work stress (PWS)
After 1 month treatment with Peg-IFN and ribavirin, we
observed significant increases (p < 0.001) in boredom, lack
of support, quantitative and qualitative overload, unsatis-
factory prospects or salary, unsatisfactory physical work-
ing conditions. After 6 months and after 12 months we
observed an increase for significant p < 0.001 compared to
Table 2 Means and standard deviations of biohumoral characteristics of subjects at baseline, at 1 month, 6 months, 12 months and
follow-up. Values are expressed as Mean (SD)
Before Treatment After 1 month After 6 months After 12 months Follow-up
AST (IU/L) 184.4 ± 37.1 180.2 ± 35.6 96.4 ± 37.4** 68.2 ± 24.9** 65.4 ± 22.1**
ALT(IU/L) 196.8 ± 36.4 185.4 ± 36.2 104.4 ± 38.1** 69.1 ± 20.6** 71.4 ± 16.1**
BILIRUBIN (mmol/L) 10.2 ± 6.8 10.2 ± 6.4 10.3 ± 6.9 10.1 ± 6.4 10.5 ± 6.1
ALBUMIN (g/dL) 4.0 ± 0.7 4.0 ± 0.6 4.1 ± 0.7 4.0 ± 0.9 4.2 ± 0.5
VIREMIA (106 IU/mL) 5.44 ± 2.20 5.22 ± 2.19 3.9 ± 2.8** 2.87 ± 2.0** 2.9 ± 1.8**
HAI 10.1 ± 3.6 - - 7.8 ± 2.9** -
Comparison between baseline and after the treatment *p < 0.05 **p < 0.01
Fig. 2 Evaluation of Percieved Work Stress in the treatment of Peg-Interferon and Ribavirin
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Fig. 3 Evaluation of Work Ability of Peg-Interferon and Ribavirin
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After 12 months, the increase were significant for all
scores with the exception of the item “unsatisfactory pros-
pects or salary”, which was not significant. At follow up
we observed significant differences in quantitative over-
load (p < 0.001). The comparison of patients’ groups, be-
fore and after the treatment, with ANOVA test shows a
decrease (p < 0.01) for all scores (Fig. 2).
Comparison in work ability index
With reference WA we observed a significant decrease
p < 0.001 after 1 month in all dimensions. After 6
months compared to baseline we observed a decrease in
subjective work ability, in number of diseases, on work
impairment, on prognosis of work ability and in mental
resource.
After 12 months we observed significant decrease sub-
jects work ability, in number of disease, in work impair-
ment, in sick leave, in prognosis of work ability, in
mental resources. The comparison of multiple groups,
before and after the treatment, with ANOVA Test show
a significant decrease (p < 0.001) for all scores (Fig. 3).
Comparison between patients according to the response
treatment in PWS
The comparison between pretreatment patients and
ETR patients show a significant decrease (p < 0.01) for
boredom, lack of support, quantitative overload, qualita-
tive overload, unsatisfactory prospects or salary, unsatis-
factory physical working conditions. The comparison
between sustained responders and pre-treated patients
show a significant decrease in boredom (p < 0.01), lack
support, quantitative overload, qualitative overload, un-
satisfactory prospects or salary, unsatisfactory physical
working conditions. No significant differences were ob-
served in boredom, in quantitative overload and in un-
satisfactory physical working conditions between non
responders and pretreated patients, while in lack of sup-
port, in qualitative overload and in unsatisfactory of sal-
ary, we observed a significant increase (p < 0.05).
In comparison with relapsers and pretreated patients we
observed no difference in boredom (p < 0.05) and in unsat-
isfactory working condition and significant difference (p <
0.05) in quantitative prospects of salary and p < 0.01 in
both lack of support and in qualitative overload. (Table 3).
Comparison between patients according to the response
treatment in WA
ETR patients compared with pretreated patients show a sig-
nificant p < 0.05 in subjective work ability, in work ability in
relations to demands, in work impairment, in prognosis of
work ability and in mental resources. No differences were
observed in number of disease and in sick leave patients.
Sustained responder compared with pretreated patientsshow a significant difference p < 0.01 in subjective work
ability, in work ability in relations to demands, in work im-
pairment, in prognosis of work ability and in mental re-
sources; (p < 0.05) in number of diseases and sick leave.
We observed no differences with pretreated patients in
non responders and in relapsers patients regarding all
dimensions (Table 4).
Table 3 Comparison between patients according to the response treatment on PWS











Boredom 1.94 ± 0.61 1.44 ± 0.56** 0.90 ± 0.37** 1.88 ± 0.62 1.98 ± 0.47
Lack of support 2.04 ± 0.44 1.87 ± 0.67* 1.84 ± 0.62* 2.22 ± 0.61* 2.44 ± 0.5**
Quantitative Overload 2.37 ± 0.65 2.04 ± 0.56** 1.87 ± 0.56** 2.44 ± 0.61 2.56 ± 0.5
Qualitative Overload 1.88 ± 0.48 1.56 ± 0.61** 1.61 ± 0.56* 2.01 ± 0.56 2.22 ± 0.41**
Unsatisfactory prospects or salary 2.10 ± 0.55 1.96 ± 0.48 1.82 ± 0.42* 2.44 ± 0.51** 2.21 ± 0.58
Unsatisfactory physical working conditions 2.02 ± 0.67 1.78 ± 0.56* 1.56 ± 0.50** 2.12 ± 0.56 2.08 ± 0.38
Comparison between Pretreatment and Responses *p < 0.05, **p < 0.001
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No serious adverse events (World Health Organization
grade 3 or 4) have been reported. 18 patients showed
mild psychological disorders such as anxiety, malaise, ir-
ritability, and depression. Median hemoglobin concen-
tration significantly fell during the first 3 months of
treatment, remaining stable for 3 months, and returning
to values similar to the baseline within 3 months after
the end of the treatment. Noteworthy, a higher decrease
of hemoglobin values was observed in the Peg-IFN plus
RBV alone treatment. The patients treated with Peg-IFN
plus RBV experienced a fall in median hemoglobin con-
centration from 13.4 g/dL (range 11.1–14.1 g/dL) to 11.0
(range 10.6–14.0 g/dL) at the end of therapy. It has been
observed a significant decrease in the white cell blood
count. The platelet counts did not significantly change.
Further, other side effects registered were anorexia
(15%), nausea (18%), weight loss (10%), headache (33%),
fatigue (51%), myalgia (34%), musculoskeletal pain
(38%), hypertriglyceridemia (41%), hypercholesterolemia
(32%), and hyperglycemia (27%). Most patients in this
clinical trial had 64% of adherence to their medication
dose and duration of therapy.
Discussion
The purpose of this study was to investigate changes in
both work ability and perceived work stress during the
treatment of HCV patients with Peg-IFN and ribavirin.
The impact of the HCV infection and antiviral therapyTable 4 Comparison between patients according to the response tr
Dimensions Pretreatment ETR
Subjective work ability 5.30 ± 0.91 6.08 ± 0.87*
Work ability in relations to demands 5.10 ± 0.88 6.16 ± 0.84*
Number of diseases 5.95 ± 0.98 6.04 ± 0.87
Work impairment 5.44 ± 1.02 6.21 ± 0.84*
Sick leave past year 5.90 ± 1.08 5.81 ± 0.87*
Prognosis of work ability 4.60 ± 1.02 6.28 ± 0.91*
Mental resources 5.00 ± 0.97 5.94 ± 0.81
Comparison between Pretreatment and Responses *p < 0.05, **p < 0.001has been investigated in several studies [10, 11, 13, 16, 17].
Various endogenous inflammatory cytokines and exogen-
ous cytokine-associated to depression and anxiety has
been correlated with specific risk factors that may allow
for potential preventive interventions. Across multiple
studies, exogenous administration of cytokines to humans
can trigger depression symptoms. Administration of cyto-
kines or activation of the innate immune system can in-
duce a behavioral repertoire, termed “sickness behavior”
that includes anhedonia, anorexia, sleep changes, and de-
creased social interaction [23]. In many illnesses cytokine
levels are cross – sectionally associated with depression
risk [24, 25].
One aspect of regaining a normal life is a high risk of
the loss of work that is associated with lower quality of
life, lower self-esteem and worse financial situations.
Previous study has showed a significant burden of HCV
infection on work productivity, use of healthcare re-
sources and related costs, and health-related quality of
life (HRQL) [14, 26, 27]. There is also much variation
in estimates of the monetary cost of productivity im-
pairments and resource utilization in HCV [28, 29].
In HCV patients treated with Peg-IFN and ribavirin,
we observed a decrease in work ability, in activities
and hobbies that are normally enjoyed, a decreased
ability to focus, concentrate or make decisions, an in-
crease in perceived work stress (Fig. 4). In our study
almost all dimensions of the WPS increased signifi-
cantly (p < 0.001) after 1 month therapy. Becauseeatment on WAI
Sustained responders Non responders Relapsers
6.78 ± 0.96** 5.34 ± 0.81 5.36 ± 0.78
6.70 ± 0.87** 5.25 ± 0.87 5.44 ± 0.81
6.44 ± 0.81* 5.91 ± 0.80 5.68 ± 0.84
6.81 ± 0.82** 5.45 ± 0.87 6.00 ± 0.82
6.72 ± 0.84* 5.84 ± 0.88 5.9 ± 0.87
* 6.41 ± 0.87** 4.71 ± 0.96 4.74 ± 0.84
6.87 ± 0.81** 5.08 ± 0.84 5.10 ± 0.88
Fig. 4 This figure summarize the results of the present study
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first month of IFN-α treatment, this clinical model
has been useful in prospectively examining various
risk factors for developing depression and fatigue. At
follow up we observed improvements of prospects
and on working conditions and work ability. The de-
crease of work ability index, during treatment, may
be due to more side effects of therapy [27]. Increased
inflammatory cytokines production and particularly
interferon (IFN-α) manifest neuropsychiatric compli-
cation such as cognitive decline and psychomotor dis-
turbance and often depression and fatigue [28]. There
is a dose-response relationship between interferon-
alpha administration and depression with a gradual
return to baseline mood after discontinuation [29–
34].
In our study both the decline of WAI and the increase
of PWS ware similar for blue and white collar workers.
This evidence indicates that workers involved in physic-
ally demanding jobs need positive physical exercise to
stay at an average level. In white collar workers the most
important changes in mental functions are related to the
weakening of precision and the speed of perception.
Nausea, somnolence, fuzzy-thinking, weight loss,
weakness, fatigue, itching are just a few of the common
symptoms that may interfere with a person work, school,
social activity and sense of well-being [31]. Debilitating
physical states requiring high cost treatments, often in
slow income patient populations, represents a burden on
the health care system [29, 30].
The present study showed that workers affected by
HCV, treated with peg-IFNα2b plus Ribavirin, had anincrease in WPS and productivity loss, and a decrease in
work ability after 1 month treatment. In previous studies
we observed that treatment with Peg-IFN and Ribavirin
shows on increase in depression or irritable mood, in
mental and physical fatigue severity, a decrease in atten-
tion, concentration and in memory activity [16, 17]. The
decrease of PWS in SVR and in ETR is associated with a
reduction in both anxiety and depression status. Suc-
cessful eradication of HCV leads to a significant im-
provement of work ability, indicating that the perceived
work stress caused by potentially reversible. The com-
bination of IFN and ribavirin no longer represents the
therapeutic standard of care, at least for difficult to cure
HCV infected patients of genotype 1b.
The impact of interferon may be comparable with
other stressful life events and chronic diseases, like dia-
betes. Establishing the causes of reduction of work per-
formance and productivity in patients with chronic
infection is difficult, but the IFN treatment may be help
to explain the consequence of chronic inflammation
and such viral infection itself is an important factor con-
tributing to reduce work performance (Fig. 4). The
chronic inflammation is believed to signal the brain and
to give rise to neurovegetative symptoms, such as mal-
aise and among others psychiatric symptoms, such as
depression and concentration difficulties.
Conclusion
Factors that may precipitate inflammation and influence
the development of depression include medical illness,
psychosocial stress, and sleep disturbance. Viral and bac-
terial infection may involve malaise, lassitude, fatigue,
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aches, insomnia, and depression cytokine induced are all
symptoms associated to both work ability reduction and
increase perceived work stress. Chronic exposure to ele-
vated inflammatory cytokines, persistent alterations in
neurotransmitter function and behavior can lead to the
development neuropsychiatric dysfunction [35–39]. The
loss of work performance increases with infection and
with IFN treatment. Behavioral responses to cytokines can
benefit an organism by promoting conservation of energy
and allocation of resources to combat infection or recov-
ery from injury along with behaviors that may elicit care
giving from others [40, 41].
However it is important to talk with family and friends
before starting treatment so they can understand and be
supportive if need to cancel or adjust plans.
The new treatments with telaprevir and boceprevir have
resulted in a higher rate of SVR, but the new interferon-
free treatment has replaced these antiviral agents. The
expanding treatment and the access to the highly effective
cure of all HCV patients not only may improve the clinical
outcomes but also patient-reported outcomes such as
health-related quality of life and work productivity, resulting
in comprehensive benefit to patients and the society [42].
Sustained responders had significant improvements is
their job performance, reaching levels of WAI and de-
crease of PWS.
Our observational study population has an important
limitation due to ethical reasons: our study design have
considered patients treated with IFN and Ribavirin in
absence of a non-treated group control. The absence of
a non-treated group control does not consent us to
understand whether the WAI and PWS differences exist
because of the treatment or the chronic infection itself.
However, our study suggests that the therapy with IFN
and Ribavirin has a negative impact on the first month
of treatment on job performance, but in the following
months, the treatment reduce side effects, viral burden,
and improve biochemical values. Moreover, the better
tolerance to IFN and Ribavirin reduce PWS and improve
WAI. Significant differences between pre-treated, re-
sponders, relapsers and non responders does not allow
us to have a definitive answer to the question: “does the
WAI and PWS depends on IFN and Ribavirin treatment
or HCV infection?”. However these data suggest that the
therapeutic response on virus infection improve the job
performance and reduce PWS.
Also the changes on work performance were linked to
changes in clinical markers of chronic hepatitis C (ALT
levels and viral burden). The greatest benefits were
achieved by patients who had improvements.
Caution should be used in interpreting these results
and extrapolating them to the HCV patients undergoing
evaluation and therapy.The pattern of changes seen across responders, non-
responders and relapsers group suggest that patients’
awareness of their response to therapy cannot explain all
the observed job performance change.
Successful antiviral therapy in associated with clinically
meaningful, significant improvements in job performance.
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